IST5 had no inhibitory activity on TrkB (Table 1), and there were no changes in behavior or signs of ataxia, dizziness or confusion in IST5-treated mice (100 mg/kg) or cognitive functions, as assessed by previously described approaches [60,61,62]. The gene discussed is NTRK2; the disease is cerebellar ataxia.